E-Posters - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION 06.00 - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION - 06.02 - GENETICS, OMICS AND BIOMARKERS P2587 - ESOC25-1868 DYNAMIC GENE EXPRESSION IN EXPERIMENTAL SUBARACHNOID HEMORRHAGE Emelie Fungbrant 1 , Jesper Bmers 2 , Anja Holm Nordvang 3 , Kristian Agmund Haanes 4 , Lars Edvinsson 5 , Tiit Mathiesen 6 1 Department of Neurosurgery, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, Department of Clinical Experimental Research, Glostrup Research Institute, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600 Glostrup, Denmark., Copenhagen, Denmark, 2 Department of Clinical Experimental Research, Glostrup Research Institute, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600 Glostrup, Denmark., copenhagen, Denmark, 3 Department of Clinical Experimental Research, Glostrup Research Institute, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600 Glostrup, Denmark., Copenhagen, Denmark, 4 Department of Clinical Experimental Research, Glostrup Research Institute, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600 Glostrup, Denmark, Department of Biology, Section of Cell Biology and Physiology, University of Copenhagen, Denmark, Copenhagen, Denmark, 5 Division of Experimental Vascular Research, Department of Clinical Sciences, Lund University Hospital, Lund, Sweden., Copenhagen, Denmark, 6 Department of Neurosurgery, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark Background and Aims: Delayed cerebral ischemia (DCI) following subarachnoid hemorrhage (SAH) leads to significant morbidity, with few patients returning to full-time employment
Thank you for thinking of posting this it will be a great practical help for people,the situation at the moment is criminal,so many people are suffering needlessly
Diagnosing Peripheral Neuropathy in Patients with Alcohol Use Disorder
Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity
The American Medical Association advises people to consult a physician before using them, in a statement saying it recommends: That unapproved synthetic peptide products undergo FDA regulatory review, and third-party testing to demonstrate their safety and efficacy before marketing or clinical use." Hearings will get underway Thursday, and those interested can watch the proceedings at the following link.
